TScan Therapeutics (TScan Therapeutics) Financial Strength : 5 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is TScan Therapeutics Financial Strength?

TScan Therapeutics has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

TScan Therapeutics did not have earnings to cover the interest expense. TScan Therapeutics's debt to revenue ratio for the quarter that ended in Dec. 2023 was 3.20. As of today, TScan Therapeutics's Altman Z-Score is 0.41.

Competitive Comparison of TScan Therapeutics's Financial Strength

For the Biotechnology subindustry, TScan Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TScan Therapeutics's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Financial Strength distribution charts can be found below:

* The bar in red indicates where TScan Therapeutics's Financial Strength falls into.

TScan Therapeutics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

TScan Therapeutics's Interest Expense for the months ended in Dec. 2023 was $-0.85 Mil. Its Operating Income for the months ended in Dec. 2023 was $-21.36 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $85.84 Mil.

TScan Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is

TScan Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

TScan Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio	=	Total Debt (Q: Dec. 2023 )			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6.593	+	85.84)	/	28.844
	=	3.20

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

TScan Therapeutics has a Z-score of 0.41, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 0.41 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TScan Therapeutics (NAS:TCRX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

TScan Therapeutics has the Financial Strength Rank of 5.

TScan Therapeutics Financial Strength Related Terms

Thank you for viewing the detailed overview of TScan Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.

TScan Therapeutics (TScan Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TScan Therapeutics Inc (NAS:TCRX) » Definitions » Financial Strength

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.tscan.com

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Executives

Timothy J Barberich	director	40 ELM ST, CONCORD MA 01752
Barbara Klencke	director	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Leiden Dworak	officer: Chief Accounting Officer	C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451
Lynx1 Capital Management Lp	10 percent owner	151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607
Weston Nichols	10 percent owner	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Brian M. Silver	officer: Chief Financial Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Debora Barton	officer: Chief Medical Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
David P Southwell	director, officer: Chief Executive Officer	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014